Astellas Pharma launches novel treatment for diabetic adults with CKD in Egypt

EGYPT – Astellas Pharma Inc. launched a novel treatment indicated for adult patients in Egypt with anemia associated with chronic kidney disease (CKD).

According to the company statement, chronic kidney disease is ranked as the fourth leading cause of death in Egypt and it is a major public health concern in the country.

CKD is a progressive disease characterized by gradual loss of kidney function and if left untreated, the debilitating condition can progress to kidney failure or early cardiovascular disease.

Anaemia is a common complication of CKD that can be observed early in the development of the condition, defined by low levels of haemoglobin.

Astellas Pharma’s new treatment could be a game changer in tackling unmet medical needs of patients with anaemia of CKD in Egypt if harnessed to its full potential.

The novel treatment has been found to be effective in increasing and maintaining target haemoglobin levels by activating the body’s natural response to reduced oxygen levels in the blood.

The response involves the regulation of multiple, coordinated processes that improve iron absorption and mobilisation, and increase red cell production, thereby help in the management of anaemia of CKD.

At Astellas, we are dedicated to uncovering unmet medical needs and driving medical solutions in nephrology that deliver value and relief to patients, their families and carers in Egypt,” said Nilay Tarr, General Manager of Astellas Egypt.

The orally-administered drug utilizes a novel mechanism of action to offer meaningful benefits and outcomes for patients, and ultimately improves their health status and quality of life.

Anaemia of CKD, left untreated or undertreated leads to “a substantial burden” on both patients and healthcare systems.

Patients with CKD and diabetes can experience a series of complications, including challenges with physical mobility, self-care and day-to-day activities among people living with the condition.

Moreover, untreated anaemia of CKD is associated with an increased risk of hospitalisation, cardiovascular complications and worsening kidney function.

Not only does it remain underdiagnosed and undertreated in Egypt but its available treatment options remain limited and often results in a conservative approach to treating the condition.

Astellas Pharma, a Japanese multinational pharmaceutical company, offers a new oral treatment option for patients with anaemia of CKD across Egypt and their treating physicians.

In addition, the first-of-its-kind treatment in Egypt offers a cost-effective approach to the management of anaemia in CKD as compared to the current standard of care.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.